Perform Another (Advanced) Search

1.  CenterWatch: Clinical Trials in Category (682) Cytomegalovirus Infections
...CenterWatch: Clinical Trials in Category (682) Cytomegalovirus Infections Cytomegalovirus Infections State • California • Indiana • Michigan • Missouri • New York • North Carolina • Ohio • Pennsylvania • Texas • Utah Country ...
View Page

2.  CenterWatch: New Medical Therapies in Disease Category (682), Cytomegalovirus Infections
...CenterWatch: New Medical Therapies in Disease Category (682), Cytomegalovirus Infections Cytomegalovirus Infections Patient Medical Areas • Immunology/Infectious Diseases July 13, 2009 Vical reported positive interim results ...
View Page

3. Clinical Trial Results: Cytomegalovirus infections
...Clinical Trial Results: Cytomegalovirus infections Clinical Trial Results: Cytomegalovirus infections Product Name: Valcyte [valganciclovir] Date of Report: 3/1/2004 Phase: III An Open ...
View Page

4.  Study Posting (4519) Trial #122541, Cytomegalovirus Infections, London, United Kingdom
...Study Posting (4519) Trial #122541, Cytomegalovirus Infections, London, United Kingdom Trial Information IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Status: No longer recruiting Protocol Number: NT18435 Sponsor: Hoffmann ...
View Page

5.  Study Posting (4519) Trial #122531, Cytomegalovirus Infections, Liverpool, United Kingdom
...Study Posting (4519) Trial #122531, Cytomegalovirus Infections, Liverpool, United Kingdom Trial Information IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Status: No longer recruiting Protocol Number: NT18435 Sponsor: Hoffmann ...
View Page

6.  Study Posting (4519) Trial #161628, Cytomegalovirus Infections, Barakaldo, Spain
...Study Posting (4519) Trial #161628, Cytomegalovirus Infections, Barakaldo, Spain Trial Information IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Status: Completed Protocol Number: NT18435 Sponsor: Hoffmann-La Roche ...
View Page

7.  Study Posting (4519) Trial #160745, Cytomegalovirus Infections, Cluj Napoca, Romania
...Study Posting (4519) Trial #160745, Cytomegalovirus Infections, Cluj Napoca, Romania Trial Information IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Status: No longer recruiting Protocol Number: NT18435 Sponsor: Hoffmann ...
View Page

8.  Study Posting (4519) Trial #124253, Cytomegalovirus Infections, Wroclaw, Poland
...Study Posting (4519) Trial #124253, Cytomegalovirus Infections, Wroclaw, Poland Trial Information IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Status: No longer recruiting Protocol Number: NT18435 Sponsor: Hoffmann ...
View Page

9.  Study Posting (4519) Trial #122600, Cytomegalovirus Infections, Krakow, Poland
...Study Posting (4519) Trial #122600, Cytomegalovirus Infections, Krakow, Poland Trial Information IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Status: No longer recruiting Protocol Number: NT18435 Sponsor: Hoffmann ...
View Page

10.  Study Posting (4519) Trial #125570, Cytomegalovirus Infections, Roma, Italy
...Study Posting (4519) Trial #125570, Cytomegalovirus Infections, Roma, Italy Trial Information IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Status: No longer recruiting Protocol Number: NT18435 Sponsor: Hoffmann ...
View Page

11.  Study Posting (4519) Trial #123785, Cytomegalovirus Infections, Regensburg, Germany
...Study Posting (4519) Trial #123785, Cytomegalovirus Infections, Regensburg, Germany Trial Information IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Status: No longer recruiting Protocol Number: NT18435 Sponsor: Hoffmann ...
View Page

12.  Study Posting (4519) Trial #125689, Cytomegalovirus Infections, Lübeck, Germany
...Study Posting (4519) Trial #125689, Cytomegalovirus Infections, Lübeck, Germany Trial Information IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Status: No longer recruiting Protocol Number: NT18435 Sponsor: Hoffmann ...
View Page

13.  Study Posting (4519) Trial #160589, Cytomegalovirus Infections, Frankfurt Am Main, Germany
...Study Posting (4519) Trial #160589, Cytomegalovirus Infections, Frankfurt Am Main, Germany Trial Information IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Status: No longer recruiting Protocol Number: NT18435 Sponsor: Hoffmann ...
View Page

14.  Study Posting (4519) Trial #123036, Cytomegalovirus Infections, Strasbourg, France
...Study Posting (4519) Trial #123036, Cytomegalovirus Infections, Strasbourg, France Trial Information IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Status: No longer recruiting Protocol Number: NT18435 Sponsor: Hoffmann ...
View Page

15.  Study Posting (4519) Trial #160433, Cytomegalovirus Infections, Clayton, Australia
...Study Posting (4519) Trial #160433, Cytomegalovirus Infections, Clayton, Australia Trial Information IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Status: No longer recruiting Protocol Number: NT18435 Sponsor: Hoffmann ...
View Page

16.  Study Posting (4519) Trial #160276, Cytomegalovirus Infections, Camperdown, Australia
...Study Posting (4519) Trial #160276, Cytomegalovirus Infections, Camperdown, Australia Trial Information IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Status: No longer recruiting Protocol Number: NT18435 Sponsor: Hoffmann ...
View Page

17.  Study Posting (4519) Trial #122805, Cytomegalovirus Infections, San Antonio, TX
...Study Posting (4519) Trial #122805, Cytomegalovirus Infections, San Antonio, TX Trial Information IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Status: No longer recruiting Protocol Number: NT18435 Sponsor: Hoffmann ...
View Page

18.  Study Posting (4519) Trial #123990, Cytomegalovirus Infections, Philadelphia, PA
...Study Posting (4519) Trial #123990, Cytomegalovirus Infections, Philadelphia, PA Trial Information IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Status: No longer recruiting Protocol Number: NT18435 Sponsor: Hoffmann ...
View Page

19.  Study Posting (4519) Trial #124058, Cytomegalovirus Infections, San Diego , CA
...Study Posting (4519) Trial #124058, Cytomegalovirus Infections, San Diego , CA Trial Information IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Status: No longer recruiting Protocol Number: NT18435 Sponsor: Hoffmann ...
View Page

20.  Study Posting (4519) Trial #123970, Cytomegalovirus Infections, Los Angeles, CA
...Study Posting (4519) Trial #123970, Cytomegalovirus Infections, Los Angeles, CA Trial Information IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients Status: No longer recruiting Protocol Number: NT18435 Sponsor: Hoffmann ...
View Page